Phagos

#Ag Tech & Green Tech

• BioTech
• DeepTech
• CleanTech
• AgriTech

BACKGROUND

Phagos is built upon a shared ideal: the use of entrepreneurship as an accelerator of positive impacts. Thereto, Adèle James, PhD in molecular microbiology,and Alexandros Pantalis, serial tech entrepreneur, are working to bring sustainable solutions to the fight against antibiotic resistance.

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY

Bacteriophages are the deadliest entities on earth. They cause billions of deaths every day—luckily only among bacteria! At Phagos, we are harnessing their exceptional potential. By optimizing bacteriophage populations, we contribute to the control of pathogenic bacteria.

CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS

Phagos was chosen by Entrepreneur First for pre-seed investment and by Wilco for its Cleantech & Agritech program.
We have demonstrated in vitro efficacy for our bacteriophages and our test results in vivo show a clear reduction in animal mortality.
We are thus preparing a seed funding campaign.

PARTNERSHIPS SOUGHT

Phagos is seeking partnerships with research labs, aquaculture and animal health actors, commercial networks in Asia, and biotech investors for seed funding.

• Further Information

  2 cofounders
  6 staff members

  STRENGTHS: Demonstration of sustainable efficacy for natural methods of infectious diseases control. Development of a novel approach to infectious diseases, potentially able to bring change to modern medicine.

  INNOVATION ASSETS: Bacteriophages show great promise in a diverse range of fields and yet their use remains experimental. We hope to give wings to their potential.

  OTHER FACTS: If solutions for it are not found, antibiotic resistance could cause more deaths than cancer by 2050. Bacteriophages are particularly promising for that quest.

  “Resistance to antibiotics could cause more deaths than cancer by 2050. In order to avoid this mounting crisis, it is urgent to develop alternatives such as phage therapy”